May 17, 2024

Plasma Protein Therapeutics Market Size to Record US$ 44.01 billion by 2032

The global plasma protein therapeutics market size is projected to touch around USD 44.01  billion by 2032 and growing at a CAGR of 5.10% over the forecast period 2023 to 2032.

Key Takeaways

  • North America contributed more than 47% of revenue share in 2022.
  • Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
  • By product type, the immunoglobulin segment has held the largest market share of 35% in 2022.
  • By product type, the albumin segment is anticipated to grow at a remarkable CAGR of 6.5% between 2023 and 2032.
  • By application, the hemophilia segment generated over 32% of revenue share in 2022.
  • By application, the primary immunodeficiency disorder segment is expected to expand at the fastest CAGR over the projected period.
  • By end user, the hospitals segment generated over 70% of revenue share in 2022.
  • By end user, the other segment is expected to expand at the fastest CAGR over the projected period.

The Plasma Protein Therapeutics Market is a dynamic sector within the pharmaceutical industry dedicated to the development and commercialization of therapeutic products derived from plasma proteins. These proteins play a crucial role in various medical treatments, including immunodeficiency disorders, hemophilia, and autoimmune diseases.

Plasma Protein Therapeutics Market Size 2023 To 2032

Growth Factors:

The market’s growth is propelled by rising awareness of plasma protein therapies, advancements in biotechnology, and an increasing prevalence of chronic diseases globally. Additionally, a surge in research and development activities, along with strategic collaborations, contributes to the expansion of the market.

Get a Sample: https://www.precedenceresearch.com/sample/3630

Plasma Protein Therapeutics Market Scope

Report Coverage Details
Growth Rate from 2023 to 2032 CAGR of 5.10%
Market Size in 2023 USD 28.13 Billion
Market Size by 2032 USD 44.01 Billion
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Product Type, By Application, and By End-user
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Region Snapshot

North America region will lead the global plasma protein therapeutics market during the forecast period 2023 to 2032. The market exhibits a global presence, with key regions including North America, Europe, Asia-Pacific, and the rest of the world. North America dominates the market due to a well-established healthcare infrastructure, while Asia-Pacific showcases significant growth potential, driven by increasing healthcare expenditure and a growing patient population.

Drivers:

Key drivers for the Plasma Protein Therapeutics Market include the growing demand for novel therapies, favorable government initiatives, and an aging population that requires advanced medical interventions. Technological innovations and the expansion of healthcare facilities in emerging economies further fuel market growth.

Challenges:

Despite its promising outlook, the market faces challenges such as stringent regulatory requirements, ethical concerns related to plasma collection, and the high cost of therapy. Addressing these challenges is crucial for sustained growth and wider accessibility of plasma protein therapeutics.

Opportunities:

Opportunities in the market lie in the untapped potential of emerging economies, where there is a growing need for improved healthcare infrastructure. Furthermore, advancements in personalized medicine and the development of novel therapeutic approaches present avenues for innovation and market expansion.

Plasma Protein Therapeutics Market Players

  • CSL Limited
  • Grifols S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • Kedrion S.p.A.
  • Shire (acquired by Takeda)
  • Bio Products Laboratory (BPL)
  • Kamada Ltd.
  • China Biologic Products Holdings, Inc.
  • Octapharma Plasma, Inc.
  • Sanquin
  • LFB S.A.
  • ADMA Biologics, Inc.
  • Bioverativ (acquired by Sanofi)

Segments Covered in the Report

By Product Type

  • Immunoglobulin
  • Albumin
  • Plasma derived factor VIII
  • Others

By Application

  • Hemophilia
  • Idiopathic thrombocytopenic purpura
  • Primary immunodeficiency disorder
  • Others

By End-user

  • Hospitals
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Plasma Protein Therapeutics Market 

5.1. COVID-19 Landscape: Plasma Protein Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Plasma Protein Therapeutics Market, By Product Type

8.1. Plasma Protein Therapeutics Market Revenue and Volume, by Product Type, 2023-2032

8.1.1 Immunoglobulin

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Albumin

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Plasma derived factor VIII

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Plasma Protein Therapeutics Market, By Application

9.1. Plasma Protein Therapeutics Market Revenue and Volume, by Application, 2023-2032

9.1.1. Hemophilia

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Idiopathic thrombocytopenic purpura

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Primary immunodeficiency disorder

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Plasma Protein Therapeutics Market, By End-user 

10.1. Plasma Protein Therapeutics Market Revenue and Volume, by End-user, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Others

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Plasma Protein Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.1.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.1.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.1.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.1.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.1.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.1.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.2.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.2.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.2.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.2.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.2.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.2.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.2.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.2.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.2.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.2.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.3.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.3.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.3.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.3.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.3.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.3.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.3.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.3.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.3.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.3.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.4.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.4.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.4.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.4.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.4.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.4.6.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.4.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.4.7.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.5.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.5.4.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)

11.5.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)

11.5.5.3. Market Revenue and Volume Forecast, by End-user (2020-2032)

Chapter 12. Company Profiles

12.1. CSL Limited

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Grifols S.A.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Takeda Pharmaceutical Company Limited

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Octapharma AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Biotest AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Kedrion S.p.A.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Shire (acquired by Takeda)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bio Products Laboratory (BPL)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Kamada Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. China Biologic Products Holdings, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *